Related Experiment Video

Updated: Jul 18, 2026

Murine Fetal Echocardiography
08:04

Murine Fetal Echocardiography

Published on: February 15, 2013

Fetal cardiomyopathy--in utero evaluation and clinical significance

Yoav Yinon1, Simcha Yagel, Juluis Hegesh

  • 1Department of Obstetric and Gynecology, the Chaim Sheba Medical Center, Tel- Hashomer, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel. yinoy@barak-online.net

Prenatal Diagnosis
|December 13, 2006
PubMed

Insights

Fetal cardiomyopathy (CM) can develop during pregnancy and be diagnosed via prenatal echocardiography. Normal mid-trimester scans do not rule out later CM development, necessitating detailed sonographic examination for neonatal outcome prediction.

Area of Science:

  • Cardiology
  • Prenatal Diagnosis
  • Fetal Medicine

Background:

  • Fetal cardiomyopathy (CM) diagnosis and outcomes are crucial for neonatal care.
  • Prenatal assessment aids in identifying and managing fetal cardiac conditions.

Observation:

  • Twelve fetuses diagnosed with CM after 23 weeks gestation, all with structurally normal hearts initially.
  • Three CM categories identified: Familial, Secondary (induced by other factors), and Idiopathic.
  • Pregnancy terminations occurred in three cases; four of nine delivered infants had favorable outcomes, while five experienced fetal/infant death.

Findings:

  • Prenatal echocardiography can diagnose fetal cardiomyopathy.
  • Normal mid-trimester fetal echocardiograms do not exclude the subsequent development of CM.
  • Secondary CM cases showed a higher rate of favorable outcomes.

Implications:

  • Detailed prenatal sonographic examination is vital for predicting neonatal outcomes in suspected fetal CM.
  • Early and accurate diagnosis of fetal CM can guide management strategies.
  • Further research into the etiology and management of fetal CM is warranted.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...